Search Result

Results for "

C4-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	3β-HSD (1) Adrenergic Receptor (1) Androgen Receptor (8) Apoptosis (4) Autophagy (1) c-Myc (2) Calmodulin (1) CDK (1) DNA/RNA Synthesis (1) Environmental Pollutants (1) Epigenetic Reader Domain (2) Fatty Acid Synthase (FASN) (1) FLAP (1) Glucocorticoid Receptor (1) Leukotriene Receptor (1) Liposome (1) NF-κB (2) NO Synthase (2) p38 MAPK (2) p62 (1) Pim (1) PKG (1) PSMA (1) Reference Standards (1) Small Interfering RNA (siRNA) (2) Sodium Channel (1) Survivin (2)
By Research Areas:	Cancer (20) Cardiovascular Disease (2) Inflammation/Immunology (4)
Oligonucleotides:	Pegylated Lipids (1) Rat Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2908

Atraric acid Methyl atrarate	Environmental Pollutants NF-κB Androgen Receptor p38 MAPK NO Synthase	Inflammation/Immunology Cancer
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

HY-12545

Brevetoxin-3 1 Publications Verification PbTx-3	Sodium Channel	Inflammation/Immunology
Brevetoxin-3 (PbTx-3) is a potent allosteric voltage-gated Na ⁺ channel activator and has multiple active centers (A-ring lactone, C-42 of R side chain) . Brevetoxin-3 (PbTx-3) has a high affinity to site 5 of the voltage-sensitive Na ⁺ channels, inhibits the inactivation of Na ⁺ channels and prolongs the mean open time of these channels. Brevetoxin-3 (PbTx-3) repeated exposures can lead to prolonged airway hyperresponsiveness (AHR) and lung inflammation .

HY-124628

IPI-9119 2 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
IPI-9119 is an orally active, selective and irreversible FASN inhibitor with an IC₅₀ of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models .

HY-122678

LQZ-7F	Survivin Apoptosis	Cancer
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC₅₀s of 2.99 and 2.47 µM, respectively .

HY-168905

SGC-CAMKK2-1	Calmodulin	Cancer
SGC-CAMKK2-1, a chemical probe, is the selective, inhibitor for calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) with an IC₅₀ of 30 nM. SGC-CAMKK2-1 inhibits AMPK phosphorylation in cell C4-2 with an IC₅₀ of 1.6 μM .

HY-112197

PKG drug G1 2 Publications Verification	PKG	Cardiovascular Disease
PKG agent G1 targets C42 of PKG Iα. PKG agent G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.

HY-163340

GA32	Glucocorticoid Receptor Androgen Receptor	Cancer
GA32 (compound 58r) is potent androgen receptor (AR)/glucocorticoid receptor (GR) dual inhibitor with IC₅₀ values of 0.13 μM and 0.83 μM for AR and GR, respectively. GA32 inhibits the proliferation of Enzalutamide (HY-70002) resistance castration-resistant prostate cancer both in vitro and in vivo .

HY-143209B

DSPE-PEG3400	Liposome	Cancer
DSPE-PEG3400 is a phospholipid-PEG polymer conjugate that can be used in drug delivery applications. DSPE-PEG3400 serves as a material for preparing nanocarriers, which is used to prolong blood circulation time, enhance stability and improve encapsulation efficiency .

HY-175592

HEAL-116	3β-HSD	Cancer
HEAL-116 is a potent, specific and orally active 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) inhibitor with an IC₅₀ of 1.18 μM and a K_D of 1.32 μM. HEAL-116 inhibits DHEA (HY-14650) metabolism and DHEA-induced target gene expression and cell proliferation. HEAL-116 can be used for cancer research, such as prostate cancer .

HY-163608

Ac-macropa	PSMA	Cancer
Ac-macropa is a PSMA-targeted Actinium-225 Conjugate, and can be used for study of prostate cancer .

HY-14165

Veliflapon BAY X 1005; DG-031	FLAP Leukotriene Receptor	Cardiovascular Disease Inflammation/Immunology
Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor . Veliflapon inhibits the synthesis of the leukotrienes B4 and C4 .

HY-175017

Survivin-IN-2	Survivin	Cancer
Survivin-IN-2 is a survivin inhibitor. Survivin-IN-2 shows cytotoxicity in cells with IC₅₀s of 0.53 μM (C4-2 cells) and 1.06 μM (PC-3 cells). Survivin-IN-2 effectively suppresses xenograft tumor growth without apparent toxicity and eliminates survivin in the tumors. Survivin-IN-2 can be used for the study of prostate cancer .

HY-161872

LC3in-C42	Autophagy p62	Cancer
LC3in-C42 is a cell-active LC3A/B and autophagy covalent inhibitor. LC3in-C42 selectively inhibits the binding of P62 to LC3A/B in vitro and at the cellular level like D5 and can function on a lower concentration .

HY-179123

ZC9	Androgen Receptor Apoptosis	Cancer
ZC9 is a novel androgen receptor (AR) degrader. ZC9 directly binds to AR and inhibits Dihydrotestosterone-induced nuclear translocation of AR. ZC9 promotes AR degradation via the ubiquitin-proteasome system and suppresses AR transcriptional activity. ZC9 significantly decreases the mRNA levels of other AR downstream genes, including PSA, TMPRSS2, and PMEPA1. ZC9 promotes Apoptosis. ZC9 exhibits anticancer activity against prostate cancer .

HY-124585

Y08060	Epigenetic Reader Domain	Cancer
Y08060 is a selective BET inhibitor. Y08060 inhibits the viability of C4-2B and LNCaP cell lines with IC₅₀ values of 3.23 and 4.41 μM. Y08060 can suppress colony formation as well as AR expression in prostate cancer cell line. Y08060 can be studied in prostate cancer research .

HY-N2908R

Atraric acid (Standard) Methyl atrarate (Standard)	Reference Standards Androgen Receptor NO Synthase p38 MAPK NF-κB	Inflammation/Immunology Cancer
Atraric acid (Standard) is the analytical standard of Atraric acid. This product is intended for research and analytical applications. Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases[1][2].

HY-121588

IMTPPE	Adrenergic Receptor	Cancer
IMTPPE is an inhibitor of the androgen receptor (AR) in C4-2 prostate cancer cells, inhibiting its transcriptional activity and protein levels. IMTPPE inhibited the proliferation of AR-positive prostate cancer cells but had no effect on AR-negative prostate cancer cells. IMTPPE also inhibited the growth of enzalutamide-resistant 22Rv1 xenograft tumors .

HY-RS25071

C4b Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
C4b Rat Pre-designed siRNA Set A contains three designed siRNAs for C4b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

C4b Rat Pre-designed siRNA Set A C4b Rat Pre-designed siRNA Set A

HY-RS02389

CDK5RAP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDK5RAP1 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK5RAP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDK5RAP1 Human Pre-designed siRNA Set A CDK5RAP1 Human Pre-designed siRNA Set A

HY-146027

Androgen receptor antagonist 4	Androgen Receptor	Cancer
Androgen receptor antagonist 4 (Compound AT2) is an androgen receptor (AR) antagonist with an IC₅₀ of 0.15 μM. Androgen receptor antagonist 4 efficiently antagonizes AR transcriptional activity, suppresses downstream target gene of AR, and blocks the DHT-induced AR nuclear translocation. Androgen receptor antagonist 4 shows anticancer activities .

HY-146026

Androgen receptor antagonist 3	Androgen Receptor	Cancer
Androgen receptor antagonist 3 (Compound C18) is an androgen receptor (AR) antagonist with an IC₅₀ of 2.4 μM. Androgen receptor antagonist 3 shows anticancer activities .

HY-142772

Y08284	Epigenetic Reader Domain	Cancer
Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity .

HY-169349

Androgen receptor antagonist 12	Androgen Receptor	Cancer
Androgen receptor antagonist 12 (Compound EF2) is an orally active Androgen receptor (AR) antagonist (IC₅₀: 0.30 μM). Androgen receptor antagonist 12 inhibits transcriptional activity of variant AR mutants and and the proliferation of AR-positive PCa cell lines. Androgen receptor antagonist 12 blocks AR nuclear translocation. Androgen receptor antagonist 12 inhibits tumor growth in a C4-2B xenograft mouse model. Androgen receptor antagonist 12 can be used for prostate cancer (PCa) research .

HY-183710

CDK9-IN-50	CDK Androgen Receptor c-Myc Apoptosis DNA/RNA Synthesis	Cancer
CDK9-IN-50 is a selective and orally active CDK9 inhibitor with an IC₅₀ of 2.2 nM. CDK9-IN-50 targets a distinct CDK9-specific subpocket to disrupt RNA polymerase II Ser2 phosphorylation and downregulate short-lived oncoproteins, including AR-V7 and Myc. CDK9-IN-50 exhibits antiproliferative activity against cancer cells, induces apoptosis and induces tumor growth inhibition in CRPC orthotopic mice models. CDK9-IN-50 can be used for the research of cancer, such as prostate cancer .

HY-186146

SGI-1776-VHL-02	Pim c-Myc Apoptosis	Cancer
SGI-1776-VHL-02 is a stereoselective PIM PROTAC degrader. SGI-1776-VHL-02 promotes the ubiquitination and degradation of PIM1, PIM2 and PIM3. SGI-1776-VHL-02 downregulates c-myc protein levels, induces Apoptosis. SGI-1776-VHL-02 has anti-cancer activity against prostate cancer. SGI-1776-VHL-02 can be used in studies related to prostate cancer .

DSPE-PEG3400	Biochemical Assay Reagents
DSPE-PEG3400 is a phospholipid-PEG polymer conjugate that can be used in drug delivery applications. DSPE-PEG3400 serves as a material for preparing nanocarriers, which is used to prolong blood circulation time, enhance stability and improve encapsulation efficiency .

Atraric acid Methyl atrarate	Structural Classification Microorganisms Classification of Application Fields Phenols Essence, Fragrance Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	Environmental Pollutants NF-κB Androgen Receptor p38 MAPK NO Synthase
Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

Brevetoxin-3 1 Publications Verification PbTx-3	Natural Products other families Classification of Application Fields Plants Inflammation/Immunology Disease Research Fields Source Classification	Sodium Channel
Brevetoxin-3 (PbTx-3) is a potent allosteric voltage-gated Na ⁺ channel activator and has multiple active centers (A-ring lactone, C-42 of R side chain) . Brevetoxin-3 (PbTx-3) has a high affinity to site 5 of the voltage-sensitive Na ⁺ channels, inhibits the inactivation of Na ⁺ channels and prolongs the mean open time of these channels. Brevetoxin-3 (PbTx-3) repeated exposures can lead to prolonged airway hyperresponsiveness (AHR) and lung inflammation .

Atraric acid (Standard) Methyl atrarate (Standard)	Microorganisms Phenols Plants	Reference Standards Androgen Receptor NO Synthase p38 MAPK NF-κB
Atraric acid (Standard) is the analytical standard of Atraric acid. This product is intended for research and analytical applications. Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases[1][2].

Cat. No.	Product Name		Classification